Q4 FY2026 · ended Jul 31, 2026 · Revenue $660,000, -13.6% YoY · Filed Oct 29, 2026
PURE Bioscience, Inc. (PURE) files with the SEC under industry code 2890, Miscellaneous Chemical Products. In Q4 of fiscal 2026, the quarter ended Jul 31, 2026, it reported revenue of $660,000 and a net loss of $610,000. As of Jul 31, 2026 it held $569,000 in cash and investments and $6.6 million in total debt.
Revenue
$660,000
-13.6% vs year-ago quarter
Net income
$-610,000
-83.7% vs year-ago quarter
Operating cash flow
$-414,000
+9.2% vs year-ago quarter
Free cash flow
—
EPS
$-0.00
-56.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
140.20M
+25.3% vs year-ago quarter
Net cash
$-6.03M
Q4 FY2026
Operating margin
-76.2%
Q4 FY2026
Company profile
- Industry
- Miscellaneous Chemical Products (SIC 2890)
- Listed as
- PURE (OTC)
- Fiscal year ends
- July 31
- Incorporated in
- DE
- Headquarters
- El Cajon, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006028
- Former names
- PURE BIOSCIENCE (until Mar 17, 2011); INNOVATIVE MEDICAL SERVICES (until Sep 2, 2003)
Other Miscellaneous Chemical Products companies
- Element Solutions Inc ESI
- Cabot Corp CBT
- WD 40 Co WDFC
- Flotek Industries INC/CN/ FTK
- Orion S.A. OEC
- ASP Isotopes Inc. ASPI
- Arq, Inc. ARQ
- Flexible Solutions International Inc FSI
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jul 31, 2026 |
Q3 FY2026 Apr 30, 2026 |
Q2 FY2026 Jan 31, 2026 |
Q1 FY2026 Oct 31, 2025 |
Q4 FY2025 Jul 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $660,000 | $506,000 | $444,000 | $708,000 | $764,000 |
| Operating income | -$503,000 | -$518,000 | -$683,000 | -$379,000 | -$336,000 |
| Net income | -$610,000 | -$624,000 | -$785,000 | -$464,000 | -$332,000 |
| Diluted EPS | -$0.00 | -$0.01 | -$0.01 | $0.00 | -$0.00 |
| Operating cash flow | -$414,000 | -$468,000 | -$606,000 | -$250,000 | -$456,000 |
| Total assets | $1.2M | $1.6M | $788,000 | $1.2M | $1.1M |
| Total liabilities | $7.6M | $7.4M | $7.1M | $6.7M | $6.2M |
| Stockholders' equity | -$6.4M | -$5.8M | -$6.3M | -$5.5M | -$5.1M |
| Cash and investments | $569,000 | $983,000 | $198,000 | $434,000 | $334,000 |
| Total debt | $6.6M | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Oct 29, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 20, 2026 | Oct 15, 2026 |
| 10-Q | Quarterly report | Jun 15, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 5, 2026 | Apr 30, 2026 |
All 1000 PURE Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.